Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment - PubMed (original) (raw)
Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment
J W Knowles et al. J Clin Invest. 2000 Feb.
Abstract
Hypertension and atherosclerosis are each important causes of morbidity and mortality in the developed world. We have investigated the interaction between these conditions by breeding mice that are atherosclerotic due to lack of apolipoprotein (apo) E with mice that are hypertensive due to lack of endothelial nitric oxide synthase (eNOS). The doubly deficient mice (nnee) have higher blood pressure (BP) and increased atherosclerotic lesion size but no change in plasma lipoprotein profiles compared with normotensive but atherosclerotic (NNee) mice. The nnee mice also develop kidney damage, evidenced by increased plasma creatinine, decreased kidney weight/body weight ratio, and glomerular lipid deposition and calcification. Enalapril treatment abolishes the deleterious effects of eNOS deficiency on BP, atherosclerosis, and kidney dysfunction in nnee mice. In striking contrast, a genetic lack of inducible NOS, which does not affect BP, has no effect on the development of atherosclerotic lesions in Apoe(-/-) mice. We also observed a positive relationship between BP and size of atherosclerotic lesions These results suggest that the atherogenic effects of eNOS deficiency can be partially explained by an increase in BP and reemphasize the importance of controlling hypertension in preventing atherosclerosis.
Figures
Figure 1
(a) BP of NNee and nnee mice. An asterisk indicates a significant increase in the BP of nnee animals compared with NNee controls (P < 0.0001). Number inside bar is sample size. (b) BP of NNee and nnee mice treated with enalapril (0.12 g/L drinking water). Two asterisks indicate a significant decrease in BP of nnee animals treated with enalapril vs. untreated animals (P < 0.001) (but not in BP of enalapril-treated vs. untreated NNee animals); (P = 0.75). Error bars represent SE.
Figure 2
(a) Left panel: Atherosclerotic lesion size expressed on a log scale in 4-month-old female NNee and nnee animals. There is an increase in the lesion size of female nnee mice compared with NNee mice. *P < 0.002. Each dot represents the mean lesion size of 4 sections from each animal. Logarithmic mean value of lesion size (in μm2) from each group is shown to the right of the dots. Data are shown as the range of logarithmic mean ± SE. Right panel: Atherosclerotic lesion size in nnee female mice is reduced by treatment with enalapril (0.12 g/L drinking water) for 2 months. **P = 0.05 compared with untreated nnee female mice. (b) Arrangement is the same as in a, except male mice are shown. *P < 0.0001 compared with NNee mice. **P < 0.02 compared with untreated nnee mice.
Figure 3
Representative histological sections from 4-month-old nnee animals. (a) Proximal aorta section showing atherosclerotic lesions. Sudan IVB with hematoxylin counterstain; ×40. Arrows indicate microaneurysms. (b) A plaque in a small vessel in myocardium. Sudan IVB with hematoxylin counterstain; ×200 (initial magnification). Arrow indicates lumen. (c) Aneurysms in an abdominal aortic section. Sudan IVB with hematoxylin counterstain; ×40 (original magnification). Arrows indicate sites of dissection. (d) Foam cells in glomerulus. Hematoxylin and eosin; ×165. Arrow indicates small area of calcification. (e) Four glomeruli demonstrating the transition from heavy lipid deposition (which appears orange) to dystrophic calcification (which appears dark blue). Sudan IVB with hematoxylin counterstain; ×82.5. (f) Glomerulus of enalapril-treated nnee mouse. Lipid deposition is light (arrow) and is confined to extraglomerular mesangial cells. Sudan IVB and hematoxylin; ×165. This pattern of lipid staining is similar to that seen in NNee mice.
Figure 4
Atherosclerotic lesion size on a log scale expressed as a function of BP in female (left) and male (right) 4-month-old mice. Genotype and drug treatments are as indicated. There is a significant relationship between BP and lesion size in both female (P < 0.01) and male (P < 0.02) mice, independent of how BP was altered (by genotype, treatment, or a combination of the two). n = 36 for females and n = 52 for males. Enal, enalapril.
Figure 5
Analysis of plasma cholesterol by fast performance liquid chromatography. There were no differences in distribution of lipoproteins from NNee mice (closed circles) and nnee mice (open diamonds).
Figure 6
Effect of iNOS deficiency on the size of atherosclerotic plaques. There is no significant difference in the atherosclerotic lesion size between iNOS+/+Apoe–/– (IIee) mice and iNOS–/–Apoe–/– (iiee) mice on normal chow. Error bars represent SE.
Figure 7
Ratios of kidney weight to body weight in 4-month-old NNee mice and nnee mice treated (+) and untreated (–) with enalapril in drinking water (0.12 g/L) for 2 months. The nnee mice show a significant decrease in the kidney weight/body weight ratio compared with NNee control mice (*P < 0.01). This decrease is abolished by enalapril treatment (**P < 0.002, nnee untreated compared with nnee treated). Error bars represent SE.
Similar articles
- Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice.
Hodgin JB, Knowles JW, Kim HS, Smithies O, Maeda N. Hodgin JB, et al. J Clin Invest. 2002 Feb;109(4):541-8. doi: 10.1172/JCI14066. J Clin Invest. 2002. PMID: 11854327 Free PMC article. - Dyslipidemia and hypertension: twin killers in renal vascular disease.
Zuccalà A. Zuccalà A. Am J Kidney Dis. 2001 Jun;37(6):1319-23. doi: 10.1053/ajkd.2001.23667. Am J Kidney Dis. 2001. PMID: 11382708 No abstract available. - Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice.
Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Ozaki M, et al. J Clin Invest. 2002 Aug;110(3):331-40. doi: 10.1172/JCI15215. J Clin Invest. 2002. PMID: 12163452 Free PMC article. - Dysfunction of endothelial nitric oxide synthase and atherosclerosis.
Kawashima S, Yokoyama M. Kawashima S, et al. Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):998-1005. doi: 10.1161/01.ATV.0000125114.88079.96. Epub 2004 Mar 4. Arterioscler Thromb Vasc Biol. 2004. PMID: 15001455 Review. - [Mice lacking the eNOS gene].
Moroi M, Namiki A, Huang PL. Moroi M, et al. Nihon Rinsho. 2004 Sep;62 Suppl 9:469-73. Nihon Rinsho. 2004. PMID: 15506429 Review. Japanese. No abstract available.
Cited by
- The beneficial health effects of puerarin in the treatment of cardiovascular diseases: from mechanisms to therapeutics.
Wan Q, Lu Q, Luo S, Guan C, Zhang H. Wan Q, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7273-7296. doi: 10.1007/s00210-024-03142-3. Epub 2024 May 6. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38709267 Review. - Convergence of coronary artery disease genes onto endothelial cell programs.
Schnitzler GR, Kang H, Fang S, Angom RS, Lee-Kim VS, Ma XR, Zhou R, Zeng T, Guo K, Taylor MS, Vellarikkal SK, Barry AE, Sias-Garcia O, Bloemendal A, Munson G, Guckelberger P, Nguyen TH, Bergman DT, Hinshaw S, Cheng N, Cleary B, Aragam K, Lander ES, Finucane HK, Mukhopadhyay D, Gupta RM, Engreitz JM. Schnitzler GR, et al. Nature. 2024 Feb;626(8000):799-807. doi: 10.1038/s41586-024-07022-x. Epub 2024 Feb 7. Nature. 2024. PMID: 38326615 Free PMC article. - Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
Watanabe K, Fujii H, Okamoto K, Kono K, Goto S, Nishi S. Watanabe K, et al. Front Endocrinol (Lausanne). 2023 Dec 19;14:1276664. doi: 10.3389/fendo.2023.1276664. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38174329 Free PMC article. - Endothelial nitric oxide synthase (eNOS) S1176 phosphorylation status governs atherosclerotic lesion formation.
Nguyen TD, Rahman NT, Sessa WC, Lee MY. Nguyen TD, et al. Front Cardiovasc Med. 2023 Nov 14;10:1279868. doi: 10.3389/fcvm.2023.1279868. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38034389 Free PMC article. - Oxidative stress and the role of redox signalling in chronic kidney disease.
Kishi S, Nagasu H, Kidokoro K, Kashihara N. Kishi S, et al. Nat Rev Nephrol. 2024 Feb;20(2):101-119. doi: 10.1038/s41581-023-00775-0. Epub 2023 Oct 19. Nat Rev Nephrol. 2024. PMID: 37857763 Review.
References
- World Health Organization. 1998. The world health report, 1998. World Health Organization. Geneva, Switzerland. 125–126.
- Braunwald E. Shattuck lecture — cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360–1369. - PubMed
- Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med. 1996;156:1952–1956. - PubMed
- Doyle, A.E. 1990. Does hypertension predispose to coronary artery disease? In Hypertension: pathophysiology, diagnosis and management. J.H. Laragh and B.M. Brenner, editors. Raven Press Ltd. New York, NY. 119–125.
- SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA. 1991;265:3255–3264. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R37 HL042630/HL/NHLBI NIH HHS/United States
- HL-62845/HL/NHLBI NIH HHS/United States
- HL-42630/HL/NHLBI NIH HHS/United States
- R01 HL049277/HL/NHLBI NIH HHS/United States
- R01 HL042630/HL/NHLBI NIH HHS/United States
- HL-49277/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous